Chemistry: analytical and immunological testing – Involving an insoluble carrier for immobilizing immunochemicals
Reexamination Certificate
2005-05-10
2005-05-10
Nguyen, Bao-Thuy L. (Department: 1641)
Chemistry: analytical and immunological testing
Involving an insoluble carrier for immobilizing immunochemicals
C436S050000, C436S063000, C436S086000, C436S089000, C436S090000, C436S173000, C436S811000, C530S300000, C530S327000, C530S328000, C530S380000, C530S381000, C530S382000
Reexamination Certificate
active
06890763
ABSTRACT:
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.
REFERENCES:
patent: 5062935 (1991-11-01), Schlag et al.
patent: 5538897 (1996-07-01), Yates, III et al.
patent: 5817768 (1998-10-01), Grieninger et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: WO 9014148 (1990-11-01), None
patent: WO 9324834 (1993-12-01), None
patent: WO 9807036 (1998-02-01), None
patent: WO 0009562 (2000-02-01), None
patent: WO 0049410 (2000-08-01), None
patent: WO 0105422 (2001-01-01), None
patent: WO 0175454 (2001-10-01), None
Strongin, Wendy, Laboratory Diagnosis of Viral Infections. Second Edition. Edited by Edwin H. Lennette. 1992.*
Tockman et al., “Considerations in Bringing a Cancer Biomarker to Clinical Applications,” Cancer Research, Suppl., 52, 2711s-2718s, May 1, 1992.*
Richter et al, Composition of the peptide fraction in human blood plasma: database of circulating human peptides, J. Chrom. B. Biomed. Sci. Appl., 726, 1-2, (1999), pp. 25-35.
Takahashi et al, Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody, Clin. Chem., 45, 8, (1999), pp. 1307-1311.
Sobel, et al., “Antipeptide Monoclonal Antibodies to Defined Fibrinogen Aα Chain Regions: Anti-Aα 487-498, a Structural Probe for Fibrinogenolysis”, Blood (1998), vol. 91, No. 5 pp. 1590-1598.
Scharfstein, et al., “Usefulness of Fibrinogenolytic and Procoagulant Markers During Thrombolytic Therapy in Predicting Clinical Outcomes in Acute Myocardial Infarction”, Am. Journal of Cardiology (1996), vol. 78, No. 5, pp. 503-510.
Database Entrez-Protein Online!, “Fibrinogen Alpha”, National Center for Biotechnology Information (NCBI), Jun. 15 (2000), Disclosed FPA sequence: aa 20-35, retrieved from www.ncbi.nlm.nih.gov.
Vaziri, et al., “Factor XIII and its substrates, fibronectin, fibrinogen, and α2-antiplasmin, in plasma and urine of patients with nephrosis”, J. Laboratory and Clinical Medicine (1991), vol. 117, No. 2, pp. 152-156.
Jackowski George
Marshall John
Thatcher Brad
Vrees Tammy
Yantha Jason
McHale & Slavin P.A.
Nguyen Bao-Thuy L.
Syn X Pharma, Inc.
LandOfFree
Biopolymer marker indicative of disease state having a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biopolymer marker indicative of disease state having a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biopolymer marker indicative of disease state having a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3399494